Impact of TP53 mutation status on cancer-specific survival after first-line treatment in lymphoplasmacytic lymphoma.

作者：Anath C. Lionel, Sherif Seif, Xiaowen Sun, Lei Feng, Lorenzo Gensini, Janelle Sanchez, Hima Bansal, Melody Becnel, Mahmoud Gaballa, Hans C. Lee, Oren Pasvolsky, Krina K. Patel, Christine Ye, Keyur P. Patel, Donna M. Weber, Robert Orlowski, Sheeba K. Thomas · 发表于：Journal of Clinical Oncology · 年份：2025 · DOI：10.1200/jco.2025.43.16_suppl.e19573 · 研究领域：Chronic Lymphocytic Leukemia Research、Lymphoma Diagnosis and Treatment、Viral-associated cancers and disorders

e19573 Background: Lymphoplasmacytic lymphoma (LPL) is an indolent B-cell neoplasm encompassing Waldenström macroglobulinemia (WM) and non-IgM LPL. Testing for MYD88 and CXCR4 mutations is part of routine clinical workup of LPL; these mutations have relevance for therapy selection since patients (pts) with MYD88 mut / CXCR4 wt LPL/WM have superior BTK inhibitor (BTKi) response rates compared to those with other mutation profiles. Previous work by our group and others has found TP53 mutations to be associated with decreased overall survival in LPL, but the impact of TP53 mutations on treatment-related outcomes is not well characterized. Methods: This retrospective single-institution study included all pts (n = 107) at our institution with a diagnosis of LPL who had next-generation sequencing (NGS) data available from bone marrow samples obtained prior to initiation of first-line treatment. The NGS panels used for this study had >250x coverage of all 10 coding exons of TP53 . Overall survival (OS) was calculated from the start date of first-line therapy; inter-group differences in OS were evaluated by log rank test. Results: The median age at diagnosis was 66 years (range 36 – 91); 56 (52%) were male and 97 (91%) were White. Median time from diagnosis to treatment initiation was 7 months and median length of follow-up from treatment initiation was 28 months (95% confidence interval (CI): 20-37 months). TP53 mutations (TP53 mut ) were found in 11/107 (10%) pts. Median TP53 va...